BDTX Overview

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Wall Street analysts forecast BDTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDTX is9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Black Diamond Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Black Diamond Therapeutics Inc. EPS for the last quarter amounts to -0.16 USD, decreased -116.33

Black Diamond Therapeutics Inc (BDTX) has 21 emplpoyees as of June 01 2026.

Today BDTX has the market capitalization of 127.21M USD.